News

Travere Therapeutics, Inc. today announced it will report first quarter 2025 financial results on Thursday, May 1, 2025, after the close of the U.S. financial markets. The Company will host a ...
Weyerhaeuser Company  today reported its first quarter 2025 financial results. The company's earnings release and associated materials are available on the Investors section of the company's website, ...
The United States stock market has recently experienced a surge, with major indices like the Dow Jones and Nasdaq Composite showing significant gains amid optimism over reduced China tariffs and ...
Scotiabank analyst Greg Harrison lowered the firm’s price target on Travere Therapeutics (TVTX) to $30 from $32 and keeps an ...
Travere Therapeutics, Inc. (NASDAQ:TVTX – Free Report) – Wedbush issued their Q1 2026 EPS estimates for shares of Travere Therapeutics in a research report issued on Wednesday, April 16th.
Travere Therapeutics (NASDAQ:TVTX – Free Report) had its target price lifted by Canaccord Genuity Group from $45.00 to $47.00 in a research note issued to investors on Thursday morning ...
SAN DIEGO--(BUSINESS WIRE)-- Travere Therapeutics, Inc. (TVTX) today announced that on April 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to six ...
Canaccord analyst Edward Nash raised the firm’s price target on Travere Therapeutics (TVTX) to $47 from $45 and keeps a Buy rating on the ...
SAN DIEGO, April 11, 2025--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on April 10, 2025, the Compensation Committee of its Board of Directors granted inducement ...
Scotiabank analyst Greg Harrison lowered the firm’s price target on Travere Therapeutics (TVTX) to $30 from $32 and keeps an Outperform rating on the shares. The company recently presented ...
Ratings for Travere Therapeutics TVTX were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table provides a quick overview of ...